本页面由Tiger Trade Technology Pte. Ltd.提供服务

Vaxcyte, Inc.

67.71
+2.694.14%
成交量:18.47万
成交额:1,229.64万
市值:100.75亿
市盈率:-8.85
高:67.75
开:64.78
低:64.78
收:65.02
52周最高:90.75
52周最低:39.87
股本:1.49亿
流通股本:1.36亿
量比:0.29
换手率:0.14%
股息:- -
股息率:- -
每股收益(TTM):-7.6496
每股收益(LYR):-5.6333
净资产收益率:-36.51%
总资产收益率:-22.61%
市净率:3.65
市盈率(LYR):-12.02

数据加载中...

2026/10/07

[补充]招股说明书

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2026/10/05

关联方拟减持公告

Form 144 | Vaxcyte, Inc. 高管 Cowan Elvia 拟减持19000股普通股,总市值约164.81万美元
2026/10/05

关联方拟减持公告

Form 144 | Vaxcyte, Inc. 高管 James Wassil 拟减持18000股普通股,合计约156.13万美元
2026/10/05

重要事件披露

Form 8-K - Current report
2026/10/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/03

重要事件披露

Form 8-K - Current report
2026/09/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/11

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/07

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/06

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/05

重要事件披露

Form 8-K - Current report
2026/08/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/07/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/07/15

重要事件披露

Form 8-K - Current report
2026/07/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities